Ivabradine to lower heart rate during exercise in healthy adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This early, dose-contrast study examines how ivabradine affects heart rate during incremental exercise in healthy adults aged 19–39 and 60–79. Participants receive two single oral doses (7.5 mg and 12.5 mg) in an unblinded, non-random design to see if higher doses produce larger reductions in peak heart rate without impacting how strongly the heart contracts. The study also monitors safety and tolerability in both age groups. Heart rate, exercise capacity, and related hemodynamic responses are evaluated to understand the specific influence of heart-rate reduction on exercise performance.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Healthy males and females aged 19-39 years, and 60-79 years
* Engaging in regular aerobic exercise (e.g., running, cycling, swimming, hiking, field, ice, or racquet sports) at least once per week

Exclusion Criteria:

* History of any cardiovascular condition, including hypertension
* Use of any chronic medication
* History of any respiratory condition, including asthma
* Smoking, including cannabis or vaping in the past year
* History of diabetes mellitus, cancer, hepatic, renal or any other chronic illness
* Seated blood pressure ≥130/90 or \<100/60 mmHg
* Body mass index \<20 or \>32 kg/m2
* Non-sinus rhythm or abnormalities on 12-lead electrocardiogram (ECG)
* Pregnant, breastfeeding, or women of childbearing potential not using appropriate contraception
* Current or recent (past year) participation in \>150 minutes per week of moderate-vigorous intensity exercise (to avoid endurance training-related bradycardia)
* Any condition that prevents vigorous exercise from being performed safely
* Seated resting heart rate \<60 beats per minute
* Prolonged QT interval (e.g., long QT syndrome)
* Sick sinus syndrome, sino-atrial block or third-degree atrio-ventricular block
* Use of strong cytochrome P450 (CYP3A4) inhibitors (e.g., nirmatrelvir and ritonavir, ketoconazole), which can increase ivabradine levels in the blood to potentially unsafe levels
* Use of verapamil or diltiazem, which are moderate CYP3A4 inhibitors and also lower heart rate, posing a risk of excessive bradycardia when combined with ivabradine
* Lactose intolerance, as ivabradine contains lactose
* Known allergy/hypersensitivity to ivabradine or to any ingredient in the formulation or component of the container

Where it's running

• SportsCardiologyBC, UBC Hospital
  Vancouver, British Columbia, Canada Recruiting

Study contacts

• Study coordinator: Stephen P Wright, PhD
• Email: stephen.wright@ubc.ca
• Phone: 604-806-9292

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Oura Ring validation for sleep using gold-standard sleep tests

  This study tests how well the Oura Ring matches the gold-standard sleep test ( PSG ) in healthy adults and people with sleep apnea.

  Recruiting Ouraring Inc. · St Louis, Missouri · NCT07908199

• Magnetic field maps with NV sensors for non-invasive heart measurements

  This study tests whether diamond-based NV magnetometers can non-invasively detect and map the heart's magnetic field in healthy adults.

  Recruiting Robert Bosch GmbH · Renningen · NCT07908173

• Cognitive Tasks and Models in a Large Online Sample

  This study tests cognitive tasks and computational models in a large online group to see if these tools can help predict symptoms like hallucinations and delusions in the general population.

  Recruiting at 2 sites Washington University School of Medicine · Minneapolis, Minnesota and 1 other locations · NCT07900893

• Single-dose study of DTI-117 given by injection in healthy adults

  Researchers are testing a one-time dose of DTI-117 in healthy adult volunteers to see if it is safe and how it moves through the body.

  Recruiting Phase 1 Dignify Therapeutics · Austin, Texas · NCT07882472

• Data-driven rural wellness interventions for vitality and endurance (DRIVE) pilot

  This pilot test will see if personalized wellness coaching based on genomic, clinical, behavioral, and functional data can be feasibly delivered in a rural setting and improve cardiometabolic, cognitive, mental health, and functional outcomes over four months.

  Recruiting McLaughlin Research Institute for Biomedical Sciences, Inc. · Great Falls, Montana · NCT07872995

• White potato meals and when you eat them: how timing changes blood sugar and appetite

  This study tests how eating white potatoes with meals at different times affects blood sugar, hunger, and how much people eat later in healthy adults.

  Recruiting Toronto Metropolitan University · Toronto, Ontario · NCT07854938

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.